Comparison of Postextubation Outcomes Associated with High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients at High Risk of Reintubation: a Randomized Clinical Trial

Jun Yeun Cho, Hee-Sung Kim, Hyeran Kang, Sun-Hyung Kim, Kang Hyeon Choe, Ki Man Lee, and Yoon Mi Shin

Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea

ABSTRACT

Background: Liberation and extubation are important for patients supported by mechanical ventilation. Extubation success is related to the duration of an intensive care unit (ICU) stay and mortality rate. High-flow nasal cannula (HFNC) oxygen therapy has physiological and clinical benefits in respiratory care. The present study compared clinical outcomes associated with HFNC and conventional oxygen therapy (COT) among patients at high risk for reintubation.

Methods: A single-center randomized clinical trial was conducted between March 2018 and June 2019. Sixty adults admitted to the ICU and who were at high-risk of reintubation and met the inclusion criteria were enrolled in this study. “High risk” for reintubation was defined as having at least one of the following risk factors: age > 65 years, Acute Physiology and Chronic Health Evaluation II score > 12 points on extubation day, obesity, poor expectoration, airway patency problems, difficult or prolonged weaning, and more than one comorbidity. The primary outcome of interest was reintubation within 72 hours. Secondary outcomes included duration of ICU and hospital stay, mortality rate, and time to reintubation.

Results: Of 60 patients, 31 received HFNC and 29 received COT (mean age, 78 ± 7.8 vs. 76 ± 6.5 years, respectively). Reintubation rate within 72 hours did not differ between the groups (3 patients [9.7%] vs. 1 patient [3.4%), respectively). Reintubation time was shorter among patients who received COT than among patients who received HFNC (0.5 hour vs. 25 hours), but this difference was not statistically significant. Duration of ICU did not differ between the groups (14.7 ± 9.6 days vs. 13.8 ± 15.7 days, for HFNC and COT, respectively).

Conclusion: Among patients at high risk for reintubation, compared with COT, HFNC did not reduce the risk of reintubation within 72 hours.

Keywords: Nasal Cannula; Oxygen; Mechanical Ventilation; Older Adults
INTRODUCTION

High-flow nasal cannula (HFNC) oxygen therapy supplies heated and humidified oxygen via a nasal cannula device; high flow rates generate low-level positive pressure when the mouth is closed, resulting in a decrease in carbon dioxide level within the anatomic dead space. As a result, HFNC is believed to improve patient comfort, enhance the expectoration of secretions, and decrease the work of breathing. Moreover, HFNC can supply highly concentrated oxygen (up to 100%), which is not possible for conventional oxygen delivery systems. Previous studies have reported physiological and clinical benefits associated with HFNC in respiratory care.1-5

Liberation and extubation are important elements in care of patients supported by mechanical ventilation. The success rate of extubation is related to the duration of stay within an intensive care unit (ICU) and mortality rates associated with the underlying condition.6,7 Following planned extubation, selection of oxygen delivery modality is at the discretion of the attending physician. While previous studies have shown a positive effect of HFNC in postextubation patients,8-10 a recent meta-analysis that included a heterogeneous patient group,11 and a previous meta-analysis of studies on patients requiring cardiac surgery demonstrate that HFNC did not reduce reintubation rates or ICU stay duration.12

In Korea, more than half of adult patients treated within an ICU are older adults (aged > 65 years). Concurrently, respiratory insufficiency is one of the most common reasons for ICU admission.13 The present study compared clinical outcomes associated with HFNC and COT among patients at high risk for reintubation.

METHODS

Study design and patients

A single-center randomized clinical trial was conducted at the ICU of the Chungbuk National University Hospital between March 2018 and June 2019. All adult patients requiring mechanical ventilation via an endotracheal tube at a medical ICU for more than 12 hours were eligible for inclusion. Patients suitable for extubation, as confirmed by two intensivists based on the spontaneous breathing test (SBT) result were screened for eligibility. Factors indicative of high risk of reintubation were:

- Age > 65 years14,15
- Acute Physiology and Chronic Health Evaluation II (APACHE II) score > 12 points on extubation day14
- Obesity (defined as body mass index > 30)16
- Poor expectoration or airway patency problem (patients with poor expectoration had a weak cough reflex or previous history of poor expectoration or altered consciousness without sedation before extubation, confirmed by observed frequency (> 3 times during 24 hours) of tracheal suctioning after extubation)17
- Difficult or prolonged weaning17
- Multiple comorbidities (for example, heart failure or moderate to severe chronic obstructive pulmonary disease14,15).

Patients had to have at least one of these risk factors to be included in the present study. Patients (or family members, as required) who declined participation in this study were excluded.
**Liberation protocol**

Clinical liberation from the ventilator followed the ICU protocol of the Chungbuk National University Hospital, which required that patients meet the following criteria: recovery from a primary illness; inspiratory pressure ≤ 12 cmH\(_2\)O; SpO\(_2\) ≥ 92% at a fraction of inspired oxygen (FiO\(_2\)) < 50% or a positive end-expiratory pressure of 4–6 cmH\(_2\)O; pH > 7.3 in arterial blood gas analysis (ABGA); respiratory rate (RR) < 30/min; presence of triggering activity > 5 times/min; no use of a neuromuscular blocking agent; systolic blood pressure ≥ 90 mmHg, allowing low-dose inotropes administration (norepinephrine ≤ 0.08 mcg/kg/min, dopamine ≤ 5 mcg/kg/min, and dobutamine ≤ 10 mcg/kg/min).

Patients who met these criteria were subsequently tested for a shallow breath index < 105 breath/min/L. Patients who passed this test took the SBT. Patients underwent SBT with a t-piece for 30 to 120 minutes, and when the patient showed respiratory distress, we returned the patient to ventilator support during the next 24 hours. If the extubation criteria were fulfilled (alert mental status, capable of coughing or rotating the neck, SpO\(_2\) ≥ 92%, RR < 30/min, and no respiratory distress), we attempted extubation.

**Randomization and data collection**

Before planned extubation, we performed stratified randomization according to age and gender, assigning patients to HFNC oxygen therapy and COT. Baseline characteristics of the enrolled patients were recorded, including age, gender, height, body weight, primary disease that required ICU admission, underlying diseases, the date of ICU admission, intubation, extubation, and reintubation, APACHE II score on the day of extubation, vital signs (blood pressure and RR), FiO\(_2\), and the results of ABGA 30 minutes before and after extubation, and 24 hours after extubation. Data on the duration of ICU and hospital stay, and mortality rate were collected.

**Intervention**

HFNC oxygen therapy (AIRVO; Fisher & Paykel Healthcare, Auckland, New Zealand) was applied immediately after extubation in the HFNC group. The supplied FiO\(_2\) was maintained alongside the previous setting of the mechanical ventilator and adjusted to the patient’s peripheral capillary oxygen saturation (SpO\(_2\)) that was greater than 90%. The set range of flow was 30–60 L/min, adjusted based on the patient’s RR. The HFNC was maintained for over 72 hours; a switch to COT was allowed after 72 hours.

COT included use of the nasal prong, and a non-rebreather facemask was applied in this group. Oxygen flow was adjusted to the target SpO\(_2\) greater than 90%. The crossover to HFNC was not allowed. Both the HFNC and COT groups were treated by the same nursing and medical staff and had similar medical management in the ICU.

**Outcomes**

The primary outcome of interest in this study was reintubation within 72 hours. Secondary outcomes included duration of ICU and hospital stay, mortality rate, and time to reintubation. Reintubation was performed in the following clinical situations: 1) refractory hypoxemia or hypercapnia, 2) excessive respiratory secretions, 3) signs of respiratory muscle fatigue, 4) altered mental status, and 5) other situations, where reintubation was deemed necessary by the attending physician.
Statistical analysis
All statistical analyses were performed using SPSS for Windows (version 25.0; SPSS Inc., Chicago, IL, USA). Continuous variables were presented as the mean and standard deviation or median and interquartile range, whereas discrete variables were presented as frequency or percentage. The Mann–Whitney U test was used for between-group comparison of continuous variables, and Fisher’s exact test was used for between-group comparison of categorical variables. The impact of interventions on outcomes of interest was compared between groups using a paired t-test. All significance testing was two-tailed, and P values < 0.05 were considered statistically significant.

Ethics statement
The present study protocol was reviewed and approved by the Institutional Review Board of Chungbuk National University Hospital (approval No. 2017-08-003). The trial was undertaken in accordance with the Declaration of Helsinki. Written informed consent was submitted by all participants at the time of enrollment.

RESULTS
From March 2018 to May 2019, we screened 67 patients with at least one risk factor for reintubation; a total of 60 patients were included in the final sample (31 and 29 patients in the HFNC and COT group, respectively) (Fig. 1). Differences in baseline characteristics of the groups are detailed in Table 1. The APACHE II scores (at the time of extubation) of the HFNC group were higher than the scores of the COT group (13.3 ± 4.2 vs. 10.7 ± 3.1; P = 0.010). Frequency of high-risk factors for reintubation did not differ between two groups. Pulmonary infection was the most common reason for ICU admission and was significantly more prevalent in the HFNC than in the COT group (80.6% vs. 51.7%; P = 0.018).

Reintubation was performed in 3 patients (9.7%) in the HFNC group, and 1 patient (3.4%) in the COT group (P = 0.613) (Table 2). The median time from extubation to reintubation was 25 hours (HFNC) and 0.5 hour (COT). The length of ICU or hospital stay, and mortality rate (ICU and hospital) did not differ between the groups. We compared vital signs and ABGA data measured at the time of extubation, 30 minutes and 24 hours after extubation (Supplementary Table 1, Figs. 2 and 3). Heart rate measured after 24 hours of extubation in the HFNC group was significantly higher than that in the COT group (99.8 ± 26.3 vs. 85.0 ± 17.1, P = 0.012).
The characteristics and outcomes of four reintubated patients are detailed in Table 3. Three of four patients were initially admitted to the ICU due to pneumonia. The most common reason for reintubation was tachypnea. Only one patient survived until discharge. Differences in characteristics between patients experiencing reintubation (n = 4) and weaning success (n = 56) are detailed in Supplementary Table 2. In the HFNC group, the APACHE II score at the time of extubation was significantly higher than that in the COT group (18.3 ± 6.7 vs. 10.7 ± 3.1, P = 0.010).

Table 1. Baseline clinical and demographic characteristics of enrolled patients

| Variables                              | HFNC group (n = 31) | COT group (n = 29) | P value |
|----------------------------------------|---------------------|-------------------|---------|
| Age, yr                                | 78.8 ± 7.8          | 76.9 ± 6.5        | 0.316   |
| Men:women                              | 16:15               | 22:7              | 0.051   |
| Body mass index, kg/m²                 | 21.8 ± 3.1          | 21.8 ± 3.7        | 0.974   |
| APACHE II score at the time of extubation | 13.3 ± 4.2         | 10.7 ± 3.1        | 0.010   |
| Length of MV at the time of extubation, days | 73 ± 4.7           | 5.7 ± 5.2         | 0.262   |

High-risk factors for reintubation

| Age, > 65 yr                          | 28 (90.3)           | 29 (100.0)        | 0.238   |
| APACHE II score > 12                  | 16 (51.6)           | 8 (27.6)          | 0.058   |
| Body mass index > 25 kg/m²            | 5 (16.1)            | 7 (24.1)          | 0.048   |
| Poor expectoration or airway patency problema | 20 (64.5)        | 17 (58.6)         | 0.639   |
| Heart failure                         | 3 (9.7)             | 3 (10.3)          | 1.000   |
| Chronic obstructive pulmonary disease  | 9 (29.0)            | 9 (31.0)          | 0.866   |
| Length of mechanical ventilation > 14 days | 4 (12.9)          | 2 (6.9)           | 0.672   |

Underlying medical condition

| Hypertension                          | 19 (61.3)           | 11 (37.9)         | 0.071   |
| Diabetes mellitus                     | 10 (32.3)           | 6 (20.7)          | 0.311   |
| Chronic renal disease                 | 2 (6.5)             | 1 (3.4)           | 1.000   |
| Liver cirrhosis                       | 0 (0.0)             | 1 (3.4)           | 0.483   |
| Heart disease                         | 4 (12.9)            | 4 (13.8)          | 1.000   |
| Cerebrovascular disease               | 5 (16.1)            | 6 (20.7)          | 0.648   |
| Malignancy                            | 6 (19.4)            | 2 (6.9)           | 0.257   |
| Chronic lung disease                  | 12 (38.7)           | 13 (44.8)         | 0.631   |

Reasons for intensive care unit admission

| Pulmonary infection                    | 25 (80.6)           | 15 (51.7)         | 0.018   |
| Chronic airway disease                 | 0 (0.0)             | 2 (6.9)           | 0.299   |
| Pulmonary embolism                     | 0 (0.0)             | 2 (6.9)           | 0.299   |
| Sepsis                                 | 1 (3.2)             | 2 (6.9)           | 0.606   |
| Drug intoxication                      | 0 (0.0)             | 3 (10.3)          | 0.107   |
| Surgical                               | 1 (3.2)             | 0 (0.0)           | 1.000   |

Oxygen flow rate

| Initial flow rate, L/min              | 39.4 ± 5.7          | 3.6 ± 1.2         | N/A     |
| Maximum flow rate, L/min              | 43.9 ± 7.5          | 4.0 ± 1.3         | N/A     |
| Final flow rate at 72 hr, L/min       | 38.1 ± 8.7          | 2.2 ± 1.4         | N/A     |
| Final COT modality (nasal cannula: facial mask) | N/A               | 28:1              | N/A     |

Data are presented as number (%) or mean ± standard deviation.

HFNC = high-flow nasal cannula, COT = conventional oxygen therapy, APACHE II = Acute Physiology and Chronic Health Evaluation II, MV = mechanical ventilation, N/A = not applicable.

aAt least three instances of sputum suction were required within 24 hours after extubation.

Table 2. Primary and secondary outcomes

| Variables                              | HFNC group (n = 31) | COT group (n = 29) | P value |
|----------------------------------------|---------------------|-------------------|---------|
| Reintubation                           | 3 (9.7)             | 1 (3.4)           | 0.613   |
| Time to reintubation, median (interquartile range), hr | 25 (0.96 to 49)     | 0.5 (N/A)         | 0.083   |
| Length of ICU stay, day                | 14.7 ± 9.6          | 13.8 ± 15.7       | 0.784   |
| Length of hospital stay, day           | 37.7 ± 25.8         | 25.7 ± 20.9       | 0.054   |
| ICU death                              | 4 (12.9)            | 3 (10.3)          | 1.000   |
| Hospital death                         | 9 (29.0)            | 6 (20.7)          | 0.459   |

Data are presented as number (%) or mean ± standard deviation.

HFNC = high-flow nasal cannula, COT = conventional oxygen therapy, ICU = intensive care unit.
11.6 ± 3.3, \( P = 0.001 \)). Arterial blood pH measured at the time of extubation was significantly different between the groups (7.49 ± 0.03 vs. 7.43 ± 0.07, \( P = 0.032 \)).

**DISCUSSION**

To the best of our knowledge, this is the first randomized study to compare clinical outcomes associated with HFNC and COT in patients at high risk of reintubation in Korean population. The majority of included patients constituted older adults with chronic lung diseases. Although this was a single center study with a small sample size, it is likely to accurately reflect the characteristics of ICU patients in Korea. In contrast to previous studies, the present study involved a minimum 72-hour HFNC, which was longer than in a previous study.\[13\]
Compared to previous studies, the present study involved a relatively low rate of reintubation (6.7%). It is possible that patients with less severe illness or symptoms were included in the present study. In the study by Fernandez et al., which compared HFNC with COT, the total rate of reintubation was 13.5% (11% and 16% in HFNC and COT, respectively). This difference might be accounted for by the discrepancy in the definition of a “high-risk” patient (presence of 2 or more risk factors) and slightly greater proportion of patients with heart failure. In other studies that compared HFNC with non-invasive ventilation (NIV), reintubation rates were higher than in the present study. In the study by Hernandez et al., which included more patients with obesity and patients who required prolonged ventilation, 22.8% of patients who received HFNC required reintubation. In a study by Yoo et al., which included more patients with malignancy, and chronic lung and heart disease than did the present study, 20.6% of patients who received HFNC required reintubation.

In the present study, HFNC did not reduce the risk of reintubation, length of hospital stay, or mortality rate. HFNC oxygen therapy is associated with benefits in respiratory care, and previous studies have aimed to demonstrate its clinical superiority. Despite many advantages associated with HFNC, its superiority over COT in clinical practice remains controversial, in particular, in circumstances involving post-extubation respiratory care. Song et al. have reported that HFNC showed a higher success rate in oxygen therapy, less discomfort, and a lower RR than an air entrainment mask; however, the authors reported no significant difference between study groups in reintubation rate during the 24-hour post-extubation period. A recent meta-analysis has reported that compared to COT, HFNC might reduce postextubation respiratory failure and RR. However, the authors included a heterogeneous patient group and could not demonstrate significant differences in reintubation rates, duration of ICU stay, or mortality rates. Meanwhile, Hernandez et al. have reported that HFNC oxygen therapy for a duration of 24 hours can reduce the risk of reintubation within 72 hours in a low-risk group, but the same study did not show significant differences in reintubation rates, duration of ICU stay, or mortality rate in the high-risk group.

As HFNC is considered to have similar efficacy but better tolerability than NIV, it is widely used as postextubation modality and in postoperative care or respiratory procedures (e.g., bronchoscopy). However, the cost of HFNC in Korea is three times (17,080 won/day) the

Table 3. Clinical and demographic characteristics, and outcomes of four patients, following reintubation

| Variables                        | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|----------------------------------|-----------|-----------|-----------|-----------|
| Age, yr                          | 92        | 71        | 69        | 77        |
| Gender                           | Man       | Man       | Man       | Women     |
| Modality                         | HFNC      | HFNC      | COT       | HFNC      |
| Body mass index, kg/m²           | 19.4      | 23.7      | 22.3      | 17.9      |
| Reason for ICU admission         | Pneumonia | Pneumonia | IPF       | Pneumonia |
| Presence of chronic lung disease | Yes       | No        | No        | No        |
| APACHE II scorea                 | 16        | 16        | 16        | 28        |
| Length of mechanical ventilation, b day | 5        | 6         | 5         | 6         |
| Tracheal suctions, c No.         | 14        | 2         | 23        | 12        |
| Time to reintubation, hr         | 46        | 10        | 0.5       | 25        |
| Cause of reintubation            | Tachypnea | Tachypnea | Tachypnea | Impaired expectoration |
| Survived to discharge            | Yes       | No        | No        | No        |

HFNC = high-flow nasal cannula, COT = conventional oxygen therapy, APACHE II = Acute Physiology and Chronic Health Evaluation II, ICU = intensive care unit, IPF = idiopathic pulmonary fibrosis.
aPatient 2 (pneumoconiosis), patient 3 (asthma and destroyed lung secondary to tuberculosis); bMeasured at the time of extubation; cRequired number of tracheal suctions within 24 hours after extubation.
cost of COT (6,240 won/day), while the circuitry for HFNC requires additional costs (19,000 won) with the support of medical insurance (20% of 95,000 won). Therefore, comparisons of effectiveness are required to ensure resources are suitably allocated. Future studies should consider this aspect of care.

Patients’ comfort was not directly evaluated in the present study. We used physiologic variables to assess comfort instead of using a specific assessment tool (e.g., visual numerical scale). Except for heart rate at 24 hours after extubation, physiologic variables such as RR and P/F ratio were not different between the groups (Supplementary Table 1). Considering physiologic outcomes, flow rate changes, and COT modalities (i.e., most patients had a nasal cannula), comfort levels appear similar between two groups (Table 1).

The present study limitation was between-group heterogeneity. Recruited patients were randomized under the supervision of a statistician, using stratification based on age and gender, but not APACHE II scores. Moreover, small sample size might have contributed to between-group heterogeneity. Although our data showed higher APACHE II score in the HFNC group than in the COT group (13.3 ± 4.2 vs. 10.7 ± 3.1, \( P = 0.01 \)), it might not be a clinically significant difference, as the APACHE II score-predicted mortality rates were in the same range (APACHE II score 10 to 14 predicted a 12% mortality rate among non-operative patients).\(^\text{17}\) Further large and well-designed clinical trials are required.

In conclusion, compared with COT, HFNC did not reduce the risk of reintubation within 72 hours of planned extubation, length of hospital stay, or mortality rate among patients at high risk of reintubation. Post-extubation use of HFNC in patients at high risk of reintubation, such as older adults, has no benefit that justifies the cost.

**ACKNOWLEDGMENTS**

We would like to thank Mrs. Eun Kyung Park of Chungbuk National University Hospital, our research coordinator, for her devotion to collecting clinical data for this study.

**SUPPLEMENTARY MATERIALS**

**Supplementary Table 1**
Comparisons of physiologic data between the two groups

Click here to view

**Supplementary Table 2**
Differences between reintubation and the weaning success group

Click here to view
REFERENCES

1. Cuquemelle E, Pham T, Papon JF, Louis B, Danin PE, Brochard L. Heated and humidified high-flow oxygen therapy reduces discomfort during hypoxic respiratory failure. *Respir Care* 2012;57(10):1571-7.

2. Frat JP, Brugiere B, Ragot S, Chatellier D, Veinstein A, Goudet V, et al. Sequential application of oxygen therapy via high-flow nasal cannula and noninvasive ventilation in acute respiratory failure: an observational pilot study. *Respir Care* 2015;60(2):170-8.

3. Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. *Am J Respir Crit Care Med* 2014;190(3):282-8.

4. Sztrymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. *Intensive Care Med* 2011;37(11):1780-6.

5. Zhu Y, Yin H, Zhang R, Wei J. High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients with acute respiratory failure: a systematic review and meta-analysis of randomized controlled trials. *BMC Pulm Med* 2017;17(1):201.

6. Epstein SK, Ciubotaru RL. Independent effects of etiology of failure and time to reintubation on outcome for patients failing extubation. *Am J Respir Crit Care Med* 1998;158(2):489-93.

7. Frutos-Vivar F, Esteban A, Apezteguia C, Gonzalez M, Arabi Y, Restrepo MI, et al. Outcome of reintubated patients after scheduled extubation. *J Crit Care* 2011;26(5):502-9.

8. Rittayamai N, Tsheikuna J, Rujwit P. High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. *Respir Care* 2014;59(4):485-90.

9. Hernandez G, Vaquero C, Gonzalez P, Subira C, Frutos-Vivar F, Rialp G, et al. Effect of postextubation high-flow nasal cannula vs conventional oxygen therapy on reintubation in low-risk patients: a randomized clinical trial. *JAMA* 2016;315(13):1354-61.

10. Brotfain E, Zlotnik A, Schwartz A, Frenkel A, Koyfman L, Gruenbaum SE, et al. Comparison of the effectiveness of high flow nasal oxygen cannula vs. standard non-rebreather oxygen face mask in post-extubation intensive care unit patients. *Int Med Assoc* 2014;16(11):718-22.

11. Zhu Y, Yin H, Zhang R, Ye X, Wei J. High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients after planned extubation: a systematic review and meta-analysis. *Crit Care* 2019;23(1):180.

12. Zhu Y, Yin H, Zhang R, Wei J. High-flow nasal cannula oxygen therapy vs conventional oxygen therapy in cardiac surgical patients: a meta-analysis. *J Crit Care* 2017;38:123-8.

13. Kwak SH, Jeong CW, Lee SH, Lee HJ, Koh Y. Current status of intensive care units registered as critical care subspecialty training hospitals in Korea. *J Korean Med Sci* 2014;29(3):431-7.

14. Ferrer M, Valencia M, Nicolas JM, Bernadich O, Badia JR, Torres A. Early noninvasive ventilation averts extubation failure in patients at risk: a randomized trial. *Am J Respir Crit Care Med* 2006;173(2):164-70.

15. Thille AW, Harrois A, Schortgen F, Brun-Buisson C, Brochard L. Outcomes of extubation failure in medical intensive care unit patients. *Crit Care Med* 2011;39(12):2612-8.

16. El-Solh AA, Aquilina A, Pineda L, Dhanvantri V, Grant B, Bouquin P. Noninvasive ventilation for prevention of post-extubation respiratory failure in obese patients. *Eur Respir J* 2006;28(3):588-95.

17. Nava S, Gregoretti C, Fanfulla F, Squadrone E, Grassi M, Carlucci A, et al. Noninvasive ventilation to prevent respiratory failure after extubation in high-risk patients. *Crit Care Med* 2005;33(11):2465-70.
18. Fernandez R, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Masclans JR, et al. High-flow nasal cannula to prevent postextubation respiratory failure in high-risk non-hypercapnic patients: a randomized multicenter trial. *Ann Intensive Care* 2017;7(1):47.

19. Hernández G, Vaquero C, Colinas L, Cuena R, González P, Canabal A, et al. Effect of postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: a randomized clinical trial. *JAMA* 2016;316(15):1565-74.

20. Yoo JW, Synn A, Huh JW, Hong SB, Koh Y, Lim CM. Clinical efficacy of high-flow nasal cannula compared to noninvasive ventilation in patients with post-extubation respiratory failure. *Korean J Intern Med* 2016;31(1):82-8.

21. Song HZ, Gu JX, Xu HQ, Cui W, Zhang GS. The value of high-flow nasal cannula oxygen therapy after extubation in patients with acute respiratory failure. *Clinics (Sao Paulo)* 2017;72(9):562-7.

22. Lu Z, Chang W, Meng SS, Zhang X, Xie J, Xu JY, et al. Effect of high-flow nasal cannula oxygen therapy compared with conventional oxygen therapy in postoperative patients: a systematic review and meta-analysis. *BMJ Open* 2019;9(8):e027523.

23. Takakuwa O, Oguri T, Asano T, Fukuda S, Kanemitsu Y, Uemura T, et al. Prevention of hypoxemia during endobronchial ultrasound-guided transbronchial needle aspiration: Usefulness of high-flow nasal cannula. *Respir Investig* 2018;56(5):418-23.